REACT clinical trial supports new approach of accelerated treatment for Crohn’s disease – The final results from an international clinical trial involving nearly 2,000 patients with Crohn’s disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn’s disease.
Studies show vedolizumab is an effective treatment for Crohn’s disease and ulcerative colitis – Investigational antibody vedolizumab is an effective treatment for those suffering from ulcerative colitis (UC) and Crohn’s disease (CD) when other treatments have failed, revealed in an international clinical trial.
Work with your health care provider to find out what your personal risk is and how often you should be screened. Have you had your colon cancer screening test? – March is National Colorectal Cancer Awareness Month in US. “Colon cancer can be prevented with screening and removal of any polyps before they develop into cancer” says Sheryl M. Ness, R.N., Mayo Clinic nurse educator.
FDA approves Remicade to treat ulcerative colitis in children older than 6 years – The U.S. Food and Drug Administration approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.
This international research study, published in The Lancet, has thrown into question the current method of treating Crohn’s disease ? opening the door to a safer and more effective treatment option for sufferers of the chronic disease. – A new study established the new alternative strategy, called “top-down” therapy, to treat the patients with Crohn’s disease by employing early use of immune-suppressing drugs combined with an antibody without using steroids.
Study data show Asacol (Mesalamine) is effective in treating all extents of ulcerative colitis including isolated proctitis. Findings reinforce the benefits of Asacol for ulcerative colitis patients.
– Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.